About Dianovo

Martin Lundberg, CEO & Co-Founder of Dianovo
Vision

Diagnostic access is an infrastructure problem, not a chemistry problem. The chemistry already works; the format carrying it is around forty years old. What fails is everything built around it: the plastic cassette, the cold chain, and a supply line that rarely reaches where testing is needed most. At over two billion tests a year, that overhead alone runs to tens of thousands of tonnes of plastic that do nothing for the test.

Dianovo starts with the format. Diagnostics made on industrial rolls instead of molded one cassette at a time. Tests that ship at ambient temperature, run anywhere from a hospital to a kiosk to a field site, and leave almost nothing behind.

CENTiV™ is how we get there. A continuous cellulose roll replaces the single-use cassette. It holds its own shape, so the plastic housing falls away. One reader runs the whole menu, and a new test is new chemistry on the same hardware rather than a new device.

Healthcare is where we start, not where we stop. The same format is built to reach the places conventional supply lines cannot, and to extend into food safety, veterinary, and environmental testing.

Diagnostics designed from the format up.

Martin Lundberg

CEO & Co-Founder

Team

Eight people. Eight disciplines.

Disciplines span diagnostics, IP, embedded electronics, bioanalytical method development, chemistry and materials, software and AI, commercial strategy, and design.

Martin Lundberg

CEO & Co-Founder

Created CENTiV and leads it as system architect and strategic lead. Around ten years in consumer goods and FMCG before Dianovo, with product development experience across dietary supplements, probiotics, and food-packaging materials. Owns IP development and strategy.

Björn Lundberg

Co-Founder

Advisor across commercial strategy, branding, partnerships, market growth, and startup venture development. Background across digital marketing, growth, and market strategy. Bachelor's degree in law and political science from Lund University.

Natpapat Kaewkhao

Bioanalytical Development

PhD in Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University. Peer-reviewed publications on LC-MS/MS bioanalytical methods for antimalarial and antiparasitic drugs. Develops and validates Dianovo's test methods to regulated laboratory standards.

Dominika Chomicka

Development & Communications

Grant development, proposal work, partnerships, and external communications. Joined Dianovo in February 2026. Previously Vice President of Partnership Development at AIESEC, building partnerships and leading a team. Bachelor in legal studies. Pursuing an MSc at Lund University.

Kristoffer Westring

Digital Implementation

PhD candidate in Embedded Electronics Engineering at Lund University Faculty of Engineering (LTH). MSc in Embedded Electronics Engineering from LTH. Computer architecture and embedded systems for CENTiV.

Kidus Mikael

Software & AI

MSc in Computer Science at Blekinge Institute of Technology, specializing in applied machine learning. Earlier degree in Computer Engineering from Dire Dawa University Institute of Technology. Software and digital infrastructure for CENTiV.

Martyna Gałat

Chemistry & Materials

BSc and MSc in forensic chemistry. Trained in certified reference materials (CRMs). Works on substrate development for the lead donor-blood test.

Disa Wigblad

Design

Product and UX/UI designer based in Malmö. Designer since 2016, formally trained at Medieinstitutet (Malmö). Led product and brand design for Fairity, Pinteg AB's GDPR data-protection SaaS, launched 2023. Leads product and UX design for the reader and the kiosk variant.

Development status

From system definition today to certification and scale, across four milestones.

2026

Today · 2026

System defined

Platform architecture defined. Two priority filings active. Manufacturing route being established with an ISO 13485-certified Nordic roll-to-roll producer.

Non-dilutive funding pursued in parallel with the current equity round.

2027

2027 · Near-term target

Prototype integrated

Full subsystem integration. Analytical validation against reference materials in controlled laboratory conditions. Regulatory pathway formalized.

2028 to 2029

2028 to 2029 · Medium-term target

Clinical feasibility

Controlled feasibility evaluation on representative patient cohorts. Health economics and environmental-impact evidence generated in parallel.

2030+

2030 onward · Long-term target

Certification and scale

Regulatory certification, commercial deployment, and assay menu expansion across the installed reader base.